Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4316479 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2LMNAGAAPKMMEN1 | |
| SCHEMBL19876885 | 0.84 | MEN1 (0.35) | SMN1; SMN2LMNAMEN1KMT2ACA2 | |
| SCHEMBL19876883 | 0.84 | MEN1 (0.35) | SMN1; SMN2LMNAMEN1KMT2ACA2 | |
| SCHEMBL29382603 | 0.84 | MEN1 (0.35) | SMN1; SMN2LMNAMEN1KMT2ACA2 | |
| SCHEMBL11203244 | 0.78 | MAPK1 (0.38) | SMN1; SMN2LMNAGAACA2CA1 | |
| SCHEMBL11203247 | 0.78 | MAPK1 (0.38) | SMN1; SMN2LMNAGAACA2CA1 | |
| SCHEMBL1067556 | 0.75 | LMNA (0.50) | SMN1; SMN2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL1067555 | 0.75 | LMNA (0.50) | SMN1; SMN2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL11687819 | 0.74 | ALDH1A1 (0.39) | CA2CA1TP53ALDH1A1MME | |
| SCHEMBL5322277 | 0.74 | TP53 (0.33) | LMNATP53ALDH1A1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6323219-B1 | PRODRUGS AND PEPTIDES FOR ANTIINFLAMMATORY AGENTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-11-27 | — | — | US | claimed |
| CN-116785269-A | Homotaurine derivatives and uses thereof | 润佳（苏州）医药科技有限公司 | 2023-09-22 | — | — | CN | disclosed |
| WO-2017075535-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| EP-2882459-A1 | DRUG DELIVERY VEHICLE COMPRISING CONJUGATES BETWEEN TARGETING POLYAMINO ACIDS AND FATTY ACIDS | University of North Texas Health Science Center (US) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014025890-A1 | DRUG DELIVERY VEHICLE COMPRISING CONJUGATES BETWEEN TARGETING POLYAMINO ACIDS AND FATTY ACIDS | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2014-02-13 | — | — | WO | disclosed |
| US-7550423-B2 | Somatostatin antagonists | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2009-06-23 | — | — | US | disclosed |
| US-20040097418-A1 | Somatostatin antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. | 2004-05-20 | — | — | US | disclosed |
| US-6590061-B1 | Synthetic polypeptide or peptides having narrow molecular weight distribution used as telechelic polymers for synthesis of block or graft copolymers | INSTITUTE OF MACROMOLECULAR CHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 2003-07-08 | — | — | US | disclosed |
| EP-0833839-B1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMA CORP (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002100885-A2 | A PENTA- OR TETRAPEPTIDE BINDING TO SOMATOSTATIN RECEPTORS AND THE USE OF THE SAME | NOVASPIN BIOTECH GMBH (DE) | 2002-12-19 | — | — | WO | disclosed |
| US-6323219-B1 | PRODRUGS AND PEPTIDES FOR ANTIINFLAMMATORY AGENTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-11-27 | — | — | US | disclosed |
| EP-1088020-A1 | FUNCTIONALISED POLYMERS OF ALPHA-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | USTAV MAKROMOLEKULARNI CHEMIE AKADEMIE VED CESKE REPUBLIKY (CZ) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999064495-A1 | FUNCTIONALISED POLYMERS OF α-AMINO ACIDS AND THE METHOD OF PREPARATION THEREOF | ÚSTAV MAKROMOLEKULÁRNÍ CHEMIE AKADEMIE VĚD ČESKÉ REPUBLIKY (CZ) | 1999-12-16 | — | — | WO | disclosed |
| US-5827860-A | Peptidyl heterocycles useful in the treatment of thrombin related disorders | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-10-27 | — | — | US | disclosed |
| US-5827866-A | ANTICOAGULANTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-10-27 | — | — | US | disclosed |
| EP-0833839-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996040742-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATEDDISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040741-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040748-A1 | PEPTIDYL HETEROCYCLES USEFUL IN THE TREATMENT OF THROMBIN RELATED DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5523308-A | SERINE PROTEASES INHIBITORS; ORAL ANTICOAGULANTS; CHEMICAL INTERMEDIATES; DIPEPTIDES | ORTHO PHARMACEUTICAL CORPORATION | 1996-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097418-A1 | Somatostatin antagonists | SSTR5, SSTR2, SSTR4 | SMN1; SMN2 2703/4885LMNA 4502/4885GAA 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.